摘要
目的研究细胞色素P450酶2C19(CYP2C19)基因多态性与艾司西酞普兰临床效应的关系。方法用DNA微阵列芯片法分析108例经艾司西酞普兰治疗的汉族抑郁症患者的CYP2C19基因型,并分为3组代谢型;用汉密尔顿抑郁量表(HAMD)评定药物疗效,副反应量表(TESS)评定药物副反应。结果 108例患者中,CYP2C19等位基因频率分别为wt(68.52%),m1(24.07%),m2(7.41%)。共计105例患者完成为期6周的抗抑郁治疗。除治疗6周末,强代谢组的纯合子与杂合子间的HAMD评分无显著差异(P=0.094)外,其余各时间点,3组代谢型HAMD评分及减分率均有显著性差异(P<0.05)。在治疗早期,弱代谢组的TESS评分较其余2组均明显增高(P<0.05);治疗后期,3组TESS评分差异无统计学意义。结论 CYP2C19基因多态性与艾司西酞普兰的临床效应密切相关。
Objective To study the relationship between polymorphism of cytochrome P450 2C19（ CYP2C19） gene and clinical response to escitalopram in Chinese Han population. Methods One hundred and eight depression patients who was treated with escitalopram were involved in the study. The clinical responses and adverse drugs reaction（ ADR） were measured with the Hamilton rating scale for depression（ HAMD） and Treatment emergent symptoms scale（ TESS）. The CYP2C19 gene was genotyped with DNA microarray. Then the six genetypes were grouped into three metabolictypes. Results The allele frequencies were 68. 52% for wild type allele,24. 07% for allele m1,and 7. 41% for allele m2,respectively. There were 105 cases which completed antidepressive therapies for 6-weeks. There were significant differences among three metabolic groups on HAMD scores and the decreasing ratios of HAMD scores at each time point（ P 0. 05）,except between Homozygous extensive and Heterozygous extensive metabolic group after 6-week treatment. After 1-week and 2-week treatment,the TESS scores of weak metabolic group were both higher than the other two groups significantly（ P 0. 05）. However,After 6-week treatment,there was no significant difference among three metabolic groups on TESS scores（ P 0. 05）. Conclusion There exists closely correlation between polymorphism of CYP2C9 gene and clinical response to escitalopram.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2013年第12期887-889,共3页
The Chinese Journal of Clinical Pharmacology
基金
郑州大学研究生科学研究基金资助项目(12Y03408)
